SCHEMBL3556495

SCHEMBL3556495

Clc1cc(Cl)nc(NCc2ccccn2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.56
MAOB P27338 3/20 0.56
KCNH2 Q12809 2/20 0.52
KDM4E B2RXH2 3/20 0.50
HPGD P15428 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
TP53 P04637 1/20 0.50
HTT P42858 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ALDH1A1 P00352 2/20 0.49
SUMO3 P55854 1/20 0.48
SUMO2 P61956 1/20 0.48
SUMO1 P63165 1/20 0.48
PTPN11 Q06124 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13406340 0.85 CYP1A2 (0.57) KDM4ENPC1RAB9AHSD17B10ALDH1A1
SCHEMBL3976219 0.85 MAOA (0.54) MAOAMAOBKCNH2KDM4EHPGD
SCHEMBL1310429 0.84 MAOA (0.58) MAOAMAOBKCNH2KDM4EHPGD
SCHEMBL3560364 0.81 KDM4E (0.53) MAOAMAOBKCNH2KDM4EHPGD
SCHEMBL3552326 0.79 PIK3CA (0.65) KDM4ESMN1; SMN2HTTALDH1A1CYP1A2
SCHEMBL1244338 0.79 MAOA (0.70) MAOAMAOBKCNH2KDM4EHPGD
SCHEMBL3951959 0.79 KDM4E (0.58) MAOAMAOBKCNH2KDM4EHPGD
SCHEMBL24054791 0.78 LMNA (0.58) MAOAMAOBKCNH2KDM4EHPGD
SCHEMBL1044798 0.78 CDC7 (0.65) JAK2PIM1SRCCCNE1CDK2
SCHEMBL4290043 0.77 MAOA (0.58) MAOAMAOBKCNH2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7696204-B2 Pharmaceutical compounds LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2010-04-13 US disclosed
US-7696204-B2 Pharmaceutical compounds LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2010-04-13 US disclosed
US-7696204-B2 Pharmaceutical compounds LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2010-04-13 US disclosed
US-20090042884-A1 Pharmaceutical Compounds F.HOFFMANN-LA ROCHE AG (CH) 2009-02-12 US disclosed
US-20090042884-A1 Pharmaceutical Compounds F.HOFFMANN-LA ROCHE AG (CH) 2009-02-12 US disclosed
US-20090042884-A1 Pharmaceutical Compounds F.HOFFMANN-LA ROCHE AG (CH) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042884-A1 Pharmaceutical Compounds PIK3CA, JAK1, PIK3R1 MAOA 1790/4885MAOB 860/4885KCNH2 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.